New trials, publications, preprints and grants on this target, month by month.
Publication
Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Trial
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
1 Nov 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.
1 Nov 2026· Hematological oncology· PUBMED
Publication
Structure-guided identification and functional evaluation of small-molecule candidates predicted to target the LAG-3/MHC-II interface.
24 Oct 2026· Bioorganic chemistry· PUBMED
Publication
CTLA-4/PD-1, LAG-3, and TIGIT Inhibitors: Emerging Drug Targets and Combination Strategies in Hepatocellular Carcinoma.
20 Oct 2026· Current cancer drug targets· PUBMED
Trial
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
1 Oct 2026· PHASE1 · WITHDRAWN· CTGOV
Publication
Impact of obesity on LAG-3 and CTLA-4 expression in CD4+ T cells from lymph nodes of sarcoidosis patients.
25 Sept 2026· Immunobiology· PUBMED
Publication
Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer.
15 Sept 2026· Medical oncology (Northwood, London, England)· PUBMED
Publication
Anti-LAG-3 antibody treatment initiated after symptom onset extends survival in ALS model mice.
10 Sept 2026· Neuroscience research· PUBMED
Publication
LAG-3 in Diffuse Large B-Cell Lymphoma: Immunohistochemical Expression Patterns and Clinicopathological Correlations.
5 Sept 2026· Journal of clinical medicine· PUBMED
Trial
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
31 Aug 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
10 Jul 2026· Nature medicine· PUBMED
Publication
LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy.
1 Jul 2026· Frontiers in oncology· PUBMED
Publication
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.
1 Jul 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Melanoma cell-derived LAG-3 enhances CXCL1/8-driven MDSCs recruitment and immune escape via TRIM28-mediated IκBα degradation.
1 Jul 2026· Journal of advanced research· PUBMED
Publication
Immune checkpoint LAG-3 governs stage-dependent and disease-associated microglial modules in ALS model mice.
25 Jun 2026· Journal of neuroinflammation· PUBMED
Publication
Tumor-infiltrating CD8+Ki-67+ and CD8+LAG-3+ T cells are associated with improved patient survival in retroperitoneal dedifferentiated liposarcomas and leiomyosarcomas.
17 Jun 2026· Experimental and molecular pathology· PUBMED
Publication
Near-Infrared Fluorescent Probes Targeting LAG-3 for Guiding Immunomodulation and Efficacy Monitoring of Stereotactic Body Radiotherapy in Liver Cancer.
17 Jun 2026· Journal of hepatocellular carcinoma· PUBMED
Publication
Immune checkpoint crosstalk between LAG-3 and CD39/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies.
15 Jun 2026· Journal of the Egyptian National Cancer Institute· PUBMED
Publication
Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.
7 Jun 2026· Transfusion medicine reviews· PUBMED
Publication
Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity.
2 Jun 2026· Signal transduction and targeted therapy· PUBMED
Publication
NK Cell Profiling: Expression of TIGIT and LAG3 as Immune Checkpoints in Advanced Endometriosis.
1 Jun 2026· American journal of reproductive immunology (New York, N.Y. : 1989)· PUBMED
Publication
Elevated Allele Frequency of a Common Germline LAG3 Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid Leukemia.
21 May 2026· Cancers· PUBMED
Publication
Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer.
15 May 2026· Cancer research· PUBMED
Publication
Immune receptor LAG3 regulates microglia function during Alzheimer's disease.
12 May 2026· Neurobiology of disease· PUBMED
Preprint
Immune receptor LAG3 regulates microglia function during Alzheimer's disease.
12 May 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
A Potent Single-Domain Antibody Targeting LAG-3 for Efficient Tumor Immunotherapy.
4 May 2026· Current issues in molecular biology· PUBMED
Publication
LAG3 as a potential biomarker in breast cancer: integrated tissue and peripheral blood analysis reveals clinical and pathomic insights in triple-negative disease.
27 Apr 2026· Journal of translational medicine· PUBMED
Publication
Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.
23 Apr 2026· International journal of cancer· PUBMED
Publication
Elevated soluble LAG-3 in chronic hepatitis B and T-cell responses to checkpoint blockade.
22 Apr 2026· Antiviral research· PUBMED